Hillmen P, Xie J, Yong A, Waweru C, Sorof TA, Goyal RK, Davis KL. Real-world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK. EJHaem. 2021 May;2(2):219-27. doi: 10.1002/jha2.174
Laramee P, Bell M, Irving A, Brodtkorb TH. The cost-effectiveness of the integration of nalmefene within the UK healthcare system treatment pathway for alcohol dependence. Alcohol Alcohol. 2016 May;51(3):283-90. doi: 10.1093/alcalc/agv140
Niaura R, Britt DM, Shadel WG, Goldstein M, Abrams D, Brown R. Symptoms of depression and survival experience among three samples of smokers trying to quit. Psychol Addict Behav. 2001 Mar 1;15(1):13-7.
Küçükdeveci AA, McKenna SP, Kutlay S, Gürsel Y, Whalley D, Arasýl T. The development and psychometric assessment of the Turkish version of the Nottingham Health Profile. Int J Rehabil Res. 2000 Mar 1;23(1):31-8.